Makary Resigns as FDA Commissioner Following Policy Disputes - Scorecard - MDSpire

Makary Resigns as FDA Commissioner Following Policy Disputes

  • By

  • Kathryn Wighton

  • May 12, 2026

  • 2 min

Share

Clinical Scorecard: Makary Resigns as FDA Commissioner Following Policy Disputes

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationGeneral public, healthcare providers, pharmaceutical companies, pediatric patients, pregnant women
Care Setting

Key Highlights

  • Marty Makary resigned after 13 months as FDA Commissioner, effective immediately.
  • His tenure included significant policy disputes and workforce reductions, particularly during the COVID-19 pandemic.

Guideline-Based Recommendations

Diagnosis

    Management

    • Focus on vaccine policy and dietary guidance initiatives, including stakeholder engagement.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        COVID-19 vaccine removed from CDC immunization schedule, impacting recommendations for healthy pediatric patients and pregnant women.

        Clinical Best Practices

        • Support federal efforts to phase out harmful food additives, referencing FDA guidelines.
        • Encourage reduced intake of highly processed foods, citing dietary recommendations.

        References

        Original Source(s)

        Related Content